Episode 31 - Redefining the Standard: Insights from the MAPLE Trial in Obstructive HCM скачать в хорошем качестве

Episode 31 - Redefining the Standard: Insights from the MAPLE Trial in Obstructive HCM

In this episode of In the Thick of It, Dr. Florian Rader and Dr. Ahmad Masri discuss the results of the MAPLE trial, a head-to-head study comparing aficamten—a cardiac myosin inhibitor—to metoprolol in patients with symptomatic obstructive hypertrophic cardiomyopathy. The trial utilized a "double-blind" design while testing both medications at therapeutic doses to assess patient’s quality of life, cardiorespiratory fitness and cardiac biomarkers. Dr. Masri highlights unexpected findings, including the significant reduction in peak VO2 and the worsening of cardiac biomarkers like NT-proBNP in the metoprolol group. The conversation also explores how these results challenge decades of reliance on beta-blockers as a first-line therapy and demonstrate the efficacy of aficamten as a potential upfront monotherapy for improving patient feel and function.